Study summary
Another DPP-1 blocker roughly halved flare-ups in a phase 2 trial
0.41rate ratio for flare-ups vs placebo (40 mg)
What was tested
HSK31858, a once-daily DPP-1 inhibitor pill (20 mg or 40 mg), against placebo for 24 weeks, in adults with frequent flare-ups.
What they found
- Flare-up rate ratios vs placebo were 0.52 (20 mg) and 0.41 (40 mg).
- Side effects were similar to placebo, without more skin or gum problems.
What it means
A large phase 3 trial is now under way.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.